Scientific Program

Educational Session VI. Multidisciplinary Approach
Crystal 1 + Crystal 2 + Crystal 3
Chair : Young-Chul Kim (Chonnam National Univ., Korea)
Hiroaki Nomori (Kameda Medical Center)
Time Topic Speaker
11:00-11:30 Optimal Therapeutic Strategy for Non-Small Cell Lung Cancer with Mediastinal Lymph Node Metastasis Yong Chan Ahn (Sungkyunkwan Univ., Korea)
11:30-12:00 Early Stage Lung Cancer Patients with Limited Lung Function Hiroaki Nomori (Kameda Medical Center)
12:00-12:30 Small-Sized Lung Nodule, How to Approach and Treat Hee Sun Park (Chungnam National Univ., Korea)
Educational Session VII. Role of Surgery Beyond Limits
Crystal 3
Chair: Sook-Whan Sung (The Catholic Univ. of Korea, Korea)
Hiroshi Date (Kyoto Univ., Japan)
Time Topic Speaker
13:40-14:00 Surgery in High-Risk Patients Hyeong Ryul Kim (Ulsan Univ., Korea)
14:00-14:20 Surgical Treatment in Locally Advanced Lung Cancer Elie Fadel
(Hôpital Marie Lannelongue et Université Paris-Sud,France)
14:20-14:40 Role of Surgery in Advanced Lung Cancer Young Tae Kim (Seoul National Univ.,Korea)
14:40-15:00 Salvage Surgery in Lung Cancer Hiroshi Date (Kyoto Univ., Japan)
15:00-15:10 Question and Answer
Educational Session VIII. Recent Radiologic Approaches in Lung Cancer
Emerald
Chair : Jae Woo Song (Ulsan Univ., Korea)
Gilbert R. Ferretti
(Clinique universitaire de radiologie et imagerie médicale, France)
Time Topic Speaker
13:40-14:10 More than Meets The Eye: Radiomics in Lung Cancer Ho Yun Lee(Sungkyunkwan Univ., Korea)
14:10-14:40 Imaging of Immunotherapy in Lung Cancer:
Immune-Related Response and Toxicity Assessment
Gilbert R. Ferretti
(Clinique universitaire de radiologie et imagerie médicale, France)
14:40-15:10 AI in Lung Cancer Imaging; Clinical Perspective Joon Beom Seo (Ulsan Univ., Korea)
14:40-15:10 Question and Answer
Educational Session IX. RT in the Era of Immunotherapy
Crystal 3
Chair : Si Yeol Song (Ulsan Univ., Korea)
Eric Ko (Weill Cornell Medical College, USA)
Time Topic Speaker
15:40-16:10 Integrating radiotherapy and immunotherapy for the treatment of non-small cell lung carcinoma Eric Ko (Weill Cornell Medical College, USA)
16:10-16:40 Promise of Combining Radiation Therapy and Immunotherapy Si Yeol Song
(Ulsan Univ., Korea)
16:40-17:10 Combination of SBRT with Immunotherapy for Lung Cancer Patients O Kyu Noh (Ajou Univ., Korea)
Educational Session X. Bridging Medicine and Basic Science
Emerald
Chair : Ho-Young Lee (Seoul National Univ., Korea)
Christopher Alexander French(Brigham and Women's Hospital, USA)
Time Topic Speaker
15:40-16:10 Pathogenesis and Treatment of NUT Midline Carcinoma Christopher Alexander French
(Brigham and Women's Hospital, USA)
16:10-16:40 Understanding and Targeting the Key Pathways Underlying
Chemoresistance and Tumor Relapse 
Ho-Young Lee (Seoul National Univ., Korea)
16:40-17:10 Structural Variations in Lung Cancer Genomes Young Seok Ju (KAIST, Korea)
Industry-Sponsored Symposium II. [Pfizer]
Crystal 1 + Crystal 2 + Crystal 3
Chair : Dong-Wan Kim (Seoul National Univ.,Korea)
Time Topic Speaker
07:50-08:30 Navigating The Treatment Journey for Patients with Oncogene-Driven NSCLC Takashi Seto
(Kyushu Cancer Center, Japan)
Industry-Sponsored Symposium III. Luncheon [ONO/BMS]
Crystal 1 + Crystal 2 + Crystal 3
Chair: Jin Hyoung Kang (The Catholic Univ. of Korea, Korea)
Time Topic Speaker
12:30-13:10 Nivolumab, Expert strategies to optimize I-O treatment of patients with NSCLC David Heigener
(LungenClinic Grosshansdorf GmbH, Germany)
Industry-Sponsored Symposium IV. [Astrazeneca]
Crystal 1 + Crystal 2 + Crystal 3
Chair: Jae Cheol Lee (Ulsan Univ., Korea)
Time Topic Speaker
17:40-18:40 The era of precision medicine with EGFR TKI, Osimertinib: an optimal strategy to manage T790M mutant NSCLC patients James Yang (National Taiwan University Hospital, Taiwan)
Plenary Session I. Clinical Translation of Lung Cancer Genomics
Crystal1 + Crystal 2 + Crystal 3
Chair: Se Jin Jang (Ulsan Univ., Korea)
Marc Ladanyi (Memorial Sloan Kettering Cancer Center, USA)
Time Topic Speaker
09:00-09:40 Patient-Derived Lung Cancer Organoids and Normal Bronchial Organoids for Precision Cancer Medicine and Disease Modeling Se Jin Jang
(Ulsan Univ., Korea)
09:40-10:20 Lung Cancer Genomics - Post-Genomic Era Marc Ladanyi
(Memorial Sloan Kettering Cancer Center, USA)
10:20-10:30 Question and Answer
Oral Presentation I
Crystal 1
Chair: Ji-Youn Han(The Catholic Univ. of Korea, Korea)
Seung Joon Kim(The Catholic Univ. of Korea, Korea)
Time Topic Speaker
13:40-13:50 AN AUDIT OF SURVIVAL IN PATIENTS DIAGNOSED WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASIS Timothy Mitchell, United Kingdom
13:50-14:00 CLINICAL EFFECT OF ADJUVANT CHEMOTHERAPY ON NSCLC WITH HIGH-RISK FACTORS Juwhan Choi, Korea
14:00-14:10 EFFICACY AND SAFETY OF APATINIB PLUS DOCETAXEL AS THE SECOND OR ABOVE LINE TREATMENT IN ADVANCED NONSQUAMOUS NSCLC: A MULTI CENTER PROSPECTIVE STUDY Qiang Jiang, China
14:10-14:20 EGFR TYROSINE KINASE INHIBITOR COMBINED WITH CONCURRENT OR SEQUENTIAL CHEMOTHERAPY FOR ADVANCED LUNG CANCER PATIENTS OF GRADUAL PROGRESSION AFTER FIRST-LINE EGFR-TKI THERAPY: A RANDOMIZED CONTROLLED STUDY Qing Chang, China
14:20-14:30 IMPACT OF EGFR MUTATION ON CLINICAL ACTIVITY OF PD-1 INHIBITORS IN PATIENTS WITH PULMONARY ADENOCARCINOMA Jang Ho Cho, Korea
14:30-14:40 A PHASE II TRIAL OF OSIMERTINIB IN THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER HARBORING ACTIVATING EGFR MUTATION FROM CIRCULATING TUMOR DNA: LIQUIDLUNG-O-COHORT 1 Cheol-Kyu Park, Korea
14:40-14:50 A REAL WORLD STUDY OF OSIMERTINIB: ASTRIS 2ND DATA CUT-OFF KOREAN SUBGROUP ANALYSIS Sang-We Kim, Korea
14:50-15:00 Real world experience of afatinib as a first line therapy for advanced EGFR (+) lung cancer in Korea Sung Yong Lee, Korea
15:00-15:10 THE EFFECT OF LYMPHOPENIA AND RADIATION THERAPY ON IMMUNOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER : CONSIDERATION OF RADIOTHERAPEUTIC STRATEGY IN IMMUNE-ONCOLOGY ERA Sangjoon Park, Korea
Oral Presentation II
Crystal 2
Chair: Chang Hyun Kang (Seoul National Univ., Korea)
Su Ssan Kim(Ulsan Univ., Korea)
Time Topic Speaker
13:40-15:10 PREDICTION OF THE PRESENCE OF HIGH-GRADE COMPONENTS IN LUNG ADENOCARCINOMA USING NEAR-PURE RADIOMIC VALUES OF IASLC/ATS/ERS SUBTYPES Shun-Mao Yang, Taiwan
13:40-15:10 RADIOMICS FEATURES AS PROGNOSTIC FACTORS IN RESECTABLE ADENOCARCINOMA OF LUNG Jooae Choe, Korea
13:40-15:10 INTRATUMORAL AND PERITUMORAL RADIOMICS FOR THE PREDICTION OF ALK (ANAPLASTIC LYMPHOMA KINASE) AND EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR) MUTATION IN LUNG ADENOCARCINOMA Jooae Choe, Korea
13:40-15:10 NEW NODULE LUNG CANCER PROBABILITY AND SCREENING INTERVAL LENGTH: ANALYSIS OF DATA FROM THE NELSON TRIAL Joan Elias Walter, Switzerland
13:40-15:10 CHARACTERISTICS OF HARDCORE SMOKERS IN LUNG CANCER SCREENING POPULATION IN SOUTH KOREA Dong Won PARK, Korea
13:40-15:10 INCIDENCE AND LUNG CANCER PROBABILITY OF NEW SUBSOLID PULMONARY NODULES DETECTED IN LOW-DOSE CT LUNG CANCER SCREENING Marjolein A. Heuvelmans, Netherlands
13:40-15:10 LUNG CANCER PROBABILITY IN NEW PERIFISSURAL NODULES DETECTED IN A LUNG CANCER SCREENING STUDY Marjolein A. Heuvelmans, Netherlands
13:40-15:10 CLINICAL SIGNIFICANCE OF PLEURAL ATTACHMENT AND INDENTATION OF SUBSOLID LUNG ADENOCARCINOMA Hyung-Jun Kim, Korea 
13:40-15:10 TBA TBA
Oral Presentation III
Crystal 1
Chair : Chair: Mi-Young Kim (Ulsan Univ., Korea)
Seung Hun Jang(Hallym Univ., Korea)
Time Topic Speaker
15:40-15:50 SYSTEMATIC BIOBANKING AND ADVANCED INTEGRATED ‘OMICS’ ANALYSIS FOR PRECISE NON-SMALL CELL LUNG CANCER (NSCLC) DIAGNOSIS AND THERAPY: THE POLISH MOBIT PROJECT. Jacek Niklinski, Poland
15:50-16:00 FREQUENT GENETIC ALTERATIONS AND THEIR CLINICAL SIGNIFICANCE IN PATIENTS WITH THYMIC EPITHELIAL TUMORS Song Xu, China
16:00-16:10 RISK FACTORS FOR PRIMARY LUNG CANCER AMONG NON-SMOKING WOMEN IN SOUTH KOREA: A RETROSPECTIVE NATIONWIDE POPULATION-BASED COHORT STUDY Jun-Pyo Myong, Korea 
16:10-16:20 DOES ADENOCARCINOMA SUBTYPES INFLUENCE THE EFFECT OF ADJUVANT CHEMOTHERAPY FOR PATHOLOGICAL STAGE IB LUNG CANCER IN 8TH TNM STAGING SYSTEM? Hiroyuki Ito, Japan
16:20-16:30 UNIPORTAL VATS SURGERY WITH NON-INTUBATED ANESTHESIA Seha Ahn, Korea
16:30-16:40 CLINICAL OUTCOME AFTER SURGICAL RESECTION OF CLINICAL SINGLE-STATION N2 NON-SMALL CELL LUNG CANCER Kwanyong HYUN, Korea
16:40-16:50 SHORT TERM AND LONG TERM OUTCOME OF SURGERY FOR PATIENTS WITH SMALL CELL LUNG CANCER Jaewon SONG, Korea
16:50-17:00 IS STEREOTACTIC BODY RADIOTHERAPY FOR ULTRACENTRAL LUNG TUMOR A FEASIBLE OPTION? A SYSTEMIC REVIEW AND META-ANALYSIS. Chai Hong Rim, Korea
17:00-17:10 MODERATE-INTENSITY STEREOTACTIC BODY RADIOTHERAPY FOR ULTRACENTRAL LUNG TUMORS: PRELIMINARY EXPERIENCES AND A CASE SERIES. Chai Hong Rim, Korea
Oral Presentation IV
Crystal 2
Chair: Jin-Haeng Chung (Seoul National Univ., Korea)
Dae Ho Lee (Ulsan Univ., Korea)
Time Topic Speaker
15:40-15:50 THE CONCORDANCE OF TISSUE AND PLASMA EPITHELIAL GROWTH FACTOR RECEPTOR MUTATION STATUS AMONG FILIPINO PATIENTS DIAGNOSED WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CARCINOMA AT NATIONAL KIDNEY AND TRANSPLANT INSTITUTE Andrea Monica Talag-Espinosa, Philippines
15:50-16:00 CLINICAL SIGNIFICANCE OF FAST, FLUID-ASSISTED SEPARATION TECHNOLOGY, NOVEL METHODS OF ENRICHING CIRCULATING TUMOR CELLS, IN LONG-TERM FOLLOW-UP OF PATIENTS WITH ADVANCED STAGE EGFR POSITIVE NON-SMALL CELL LUNG CANCER Mi-Hyun Kim, Korea
16:00-16:10 A PHASE II, OPEN-LABEL, MULTICENTRE STUDY TO ASSESS THE ANTI-TUMOUR ACTIVITY OF AFATINIB IN PATIENTS WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION (EGFRM) FROM CIRCULATING TUMOR DNA (CTDNA) Young-Chul KIM, Korea
16:10-16:20 EXTRACELLULAR VESICLE-BASED EGFR GENOTYPING IN BRONCHOALVEOLAR LAVAGE FLUID FROM NON-SMALL CELL LUNG CANCER PATIENTS Jong Sik Lee, Korea
16:20-16:30 TARGETED SEQUENCING ANALYSIS OF PULMONARY ADENOCARCINOMA WITH MULTIPLE SYNCHRONOUS GROUND-GLASS/LEPIDIC NODULES Eunhyang Park, Korea
16:30-16:40 EARLY EXPERIENCE WITH NGS FOR IDENTIFICATION OF PREDICTIVE BIOMARKERS IN ADVANCE NSCLC Anurag Mehta, India
16:40-16:50 HIPPO EFFECTOR YAP CONTROLS AUTOPHAGY VIA REGULATING P62 IN LUNG ADENOCARCIONMA Chaeuk CHUNG, Korea
16:50-17:00 HIPPO-YAP PATHWAY MEDIATED RESISTANCE TO CRIZOTINIB IN ROS1-POSITIVE LUNG CANCER Ping-Li Sun, China
17:00-17:10 EFFICACY OF NANO-PARTICULATED, WATER-SOLUBLE ERLOTINIB AGAINST INTRACRANIAL METASTASES OF EGFR-MUTANT LUNG CANCER Jin Kyung Rho, Korea